不同新辅助化疗方案对三阴性乳腺癌治疗疗效临床分析  

Therapeutic Effect of Different Neoadjuvant Chemotherapy on Triple Negative Breast Cancer

作　　者：张明[1,2] 高嫦娥[3] 邹天宁[1,4] 杨毅[1,2] 陈德滇[1,4] 

机构地区：[1]云南省肿瘤医院 [2]昆明医科大学第三附属医院肿瘤放疗中心,云南昆明650118 [3]昆明医科大学第一附属医院肿瘤内科,云南昆明650032 [4]昆明医科大学第三附属医院乳腺科,云南昆明650118

出　　处：《昆明医科大学学报》2015年第1期65-68,88,共5页Journal of Kunming Medical University

基　　金：云南省应用基础研究基金资助项目(2012FB165);云南省科技厅-昆明医科大学联合专项基金资助项目(2011FB207)

摘　　要：目的观察新辅助化疗提高三阴性乳腺癌（TNBC）手术切除的近期疗效及3种不同新辅助化疗方案的治疗效果.方法 150例局部晚期TNBC患者随机分为3组,每组各50例,A组采取TAC（多西他赛＋表阿霉素＋环磷酰胺）方案,B组采取TC（多西他赛＋环磷酰胺）方案,C组采取CEF（表阿霉素＋氟尿嘧啶＋环磷酰胺）进行新辅助化疗,观察化疗后近期疗效与不良反应.结果 TAC组有效率为92.0%,TC组为84.0%,CEF组为76.0%,3组化疗方案1~5周期均使同侧腋淋巴结缩小,且TAC组优于TC、CEF组（P〈0.05）,3组中不良反应因予预防干预,均较少.结论 TNBC对多西他赛＋表阿霉素＋环磷酰胺较多西他赛＋环磷酰胺及表阿霉素＋氟尿嘧啶＋环磷酰胺新辅助化疗更敏感,更易获c CR.Objective To compare the efficacy of three different regimens of neoadjuvant chemotherapy on triple negative breast cancer （TNBC） Methods 150 patients with locally advanced TNBC diagnosed by immunohistochemistry were randomly divided into three groups with 50 cases in each group. Each group received different neoadjuvant chemotherapy regime as follows： TAC （docetaxel ＋ epirubicin ＋ cyclophosphamide） for group A, TC （docetaxel ＋ cyclophosphamide） for group B, and CEF （5-fluorouracil＋epirubicin ＋ cyclophosphamide） for group C. After neoadjuvant chemotherapy, the short-term effect and adverse reactions were observed. Results The effective rate of three groups was 92.0% （TAC） , 84.0% （TC） and 76.0% （CEF） , respectively. The ipsilatera] axillary lymph nodes lesions were decreased in all three groups after 1-5 cycles of chemotherapy regimens, and the effect of TAC was better than that of TC and CEF groups. Due to the prevention and intervention, adverse reactions of three groups were less. Conclusion The results showed that TAC neoadjuvant chemotherapy regime was more sensitive than TC and CEF to TNBC, which made cCR more accessible.

关 键 词：乳腺肿瘤 药物疗法 联合 预后 

分 类 号：R737.9[医药卫生—肿瘤]